REGENERON PHARMACEUTICALS, INC.REGN
REGENERON PHARMACEUTICALS, INC. Financial Overview 2021–2025
Regeneron successfully absorbed the total collapse of a $7.6 billion COVID-19 antibody revenue stream, yet still expanded its underlying core business. The central investment thesis relies on the company's ability to replace that pandemic windfall with surging collaboration revenues from its immunology blockbuster Dupixent, buying time for its broader clinical pipeline to mature. Reflecting this operational pivot, total revenues normalized from a pandemic-inflated $16.1 billion in FY2021 to $14.34 billion in FY2025.
This stabilization is powered by Sanofi collaboration revenues—primarily Dupixent—which grew 29% year-over-year to $5.88 billion in FY2025. That expansion actively offsets competitive pressures in the ophthalmology portfolio, where combined U.S. net product sales of EYLEA and EYLEA HD slipped to $4.38 billion. Management is aggressively reinvesting these cash flows into future therapies, hiking research and development expenses by 14% to $5.85 billion in FY2025. The balance sheet remains heavily capitalized, ending FY2025 with $3.12 billion in cash and cash equivalents alongside $15.40 billion in marketable securities. At the close of FY2025, the market valued the stock at $771.87, representing a P/E ratio of 18.6x on $41.48 in earnings per share.
Recent Developments (Q3 and Q4 2025)
Regeneron concluded 2025 by initiating a quarterly cash dividend and actively returning capital, deploying $2.79 billion toward stock repurchases over the first nine months. Net income reached $4.50 billion for the full year. The company absorbed an $83 million in-process research charge in Q3 2025, primarily driven by an $80 million licensing payment to Hansoh Pharmaceuticals. Additional Q4 2025 items included a $19 million research charge and a $60 million donation matching expense.
Operations faced late-year headwinds when third-party manufacturer Catalent caused FDA approval delays for the EYLEA HD pre-filled syringe and Ordspono, forcing Regeneron to onboard alternative suppliers. The bull case views the new dividend and aggressive repurchases as a signal of strong confidence in long-term pipeline execution. The bear case highlights immediate commercial vulnerabilities from EYLEA HD's delayed rollout amidst escalating biosimilar competition. Trading at 18.7x earnings as of February 3, 2026, the stock appears reasonably priced relative to these operational hurdles.
What to watch: progress onboarding alternative manufacturing suppliers; commercial impact of biosimilars on legacy EYLEA sales.
Rev
$14.34B
FY2025
NI
$4.50B
FY2025
EPS
$43.07
FY2025
OCF
$4.98B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 30, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on January 29, 2026, to announce its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release detailing these results is attached as Exhibit 99.1 and is incorporated by reference. Investors should refer to this press release for specific figures related to revenue, profitability, and operational performance. This filing is crucial for understanding the company's recent financial health and its trajectory heading into the new fiscal year. The information is being furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934, meaning it does not automatically update previous SEC filings. Investors should consult the press release directly for comprehensive details.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 12, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 12, 2026, providing a corporate update and preliminary unaudited financial information for the fourth quarter and full year 2025. The update, delivered at the J.P. Morgan Healthcare Conference, highlighted two key financial items: an anticipated acquired in-process research and development (IPR&D) charge of approximately $19 million, expected to reduce Q4 2025 diluted earnings per share by roughly $0.14 on both a GAAP and non-GAAP basis. This charge reflects investments in early-stage development projects. Additionally, the company reported a $60 million charge to selling, general, and administrative expenses in Q4 2025 related to its matching program for donations to Good Days, a non-profit supporting retinal disease research. Regeneron matched the $60 million in donations received by the Fund for this initiative.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 28, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to report its financial and operating results for the third quarter ended September 30, 2025. The company issued a press release on October 28, 2025, detailing these results, which is being furnished as an exhibit to this filing. Investors should refer to the press release (Exhibit 99.1) for specific financial figures and operational updates, as it contains the core information regarding the company's performance during the period. The filing itself primarily serves as a notification and mechanism to incorporate the press release into the SEC's public record. While the 8-K does not contain the detailed financial tables or management commentary directly, the attached press release is the key document for understanding Regeneron's recent performance and outlook. Investors are advised to review this press release thoroughly for a comprehensive understanding of the reported results.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 6, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing an expected acquired in-process research and development (IPR&D) charge of approximately $83 million on a pre-tax basis for the third quarter of 2025. This charge is primarily linked to an $80 million upfront payment made to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement. The company anticipates this IPR&D charge will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.68 for the quarter.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 1, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 1, 2025, to report its financial and operating results for the second quarter ended June 30, 2025. The primary purpose of this filing is to furnish the accompanying press release (Exhibit 99.1) which contains detailed financial and operational performance metrics for the period. Investors should refer to this press release for specific figures regarding revenue, profitability, and key product performance. This report serves as the official notification of the company's quarterly performance. While the 8-K itself is brief, it directs stakeholders to the press release for the substantive financial disclosures. Investors are advised to review the press release for insights into Regeneron's strategic progress, any notable product updates, and forward-looking guidance, which will be crucial for assessing the company's current valuation and future prospects.
View all 8-K filings →